Forbion Secures Over €2 Billion in Largest Fundraising to Date, Supporting 30 Biotechs

Fundraising Success: Forbion, a leading global life sciences venture capital firm, has raised over €2 billion across two new funds:
Forbion Growth Opportunities Fund III (€1.2 billion) and Forbion Ventures Fund VII (€890 million).

Assets Under Management:
This brings Forbion's assets under management to €5 billion, marking the firm's largest fundraising to date.

Investment Strategy:
The funds will focus on investing in development-stage life sciences companies, primarily in Europe and North America, with a focus on novel therapeutics in areas of high medical need.

Portfolio Companies:
Each fund is expected to invest in approximately 15 portfolio companies, supporting a total of 30 biotechs.

Track Record:
Forbion has a strong performance track record, including six exits of $1 billion+ within a 12-month period, and has been recognized as the Top Performing European VC Manager by Preqin's 2024 awards.

Investor Confidence:
The fundraising reflects investors' confidence in Forbion's ability to source and support innovative biotechs and deliver impactful returns, despite volatile market conditions.